risedronic acid has been researched along with Sarcoidosis, Pulmonary in 1 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Sarcoidosis, Pulmonary: Sarcoidosis affecting predominantly the lungs, the site most frequently involved and most commonly causing morbidity and mortality in sarcoidosis. Pulmonary sarcoidosis is characterized by sharply circumscribed granulomas in the alveolar, bronchial, and vascular walls, composed of tightly packed cells derived from the mononuclear phagocyte system. The clinical symptoms when present are dyspnea upon exertion, nonproductive cough, and wheezing. (Cecil Textbook of Medicine, 19th ed, p431)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arai, T | 1 |
| Inoue, Y | 1 |
| Hayashi, S | 1 |
| Yamamoto, S | 1 |
| Sakatani, M | 1 |
1 other study available for risedronic acid and Sarcoidosis, Pulmonary
| Article | Year |
|---|---|
Risedronate induced BOOP complicated with sarcoidosis.
Topics: Aged; Calcium Channel Blockers; Cryptogenic Organizing Pneumonia; Etidronic Acid; Female; Humans; Mu | 2005 |